Top

Published in:

01-08-2008 | Leading Article

Assessing the Impact of Global Price Interdependencies

Author: Associate Professor Anke Richter

Published in: PharmacoEconomics | Issue 8/2008

Abstract

Documented launch delays and the ensuing debate over their underlying causes have focused on assessment from the individual country’s perspective. Seen in a larger game theoretical framework this may cause problems, because although the countries see an individual game, the pharmaceutical firm sees a repeated linked game. The links are due to external reference pricing and parallel trade. Behaviours that are optimal in the single, individual game (for either the country or the pharmaceutical firm) may no longer be optimal when considering the global repeated game.

A theoretical mixed integer linear model of the firm’s launch and pricing decisions is presented along with examples wherein international price dependencies most likely played a role. This model can help countries understand the implication of their external reference pricing policies on the global repeated pricing game. Understanding the behaviour of the pharmaceutical firm in this global context aids countries in designing policies to maximize the welfare of their citizens.

Available only for authorised users

There are many different ways of determining the groupings of ‘equivalent’ drugs. Some countries only look at classifications with drugs that have the same chemical compound, whereas other countries consider all the medications that are available to treat a certain therapeutic group.

Danzon PM, Wang R, Wang L. The impact of price regulation on the launch delay of new drugs: evidence from twenty-five major markets in the 1990s. Health Econ 2005; 14: 269–292PubMedCrossRef

Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat 2007; 89 (1): 88–99CrossRef

Lanjow JO. Patents, price controls and access to new drugs: how policy affects global market entry. NBER working paper no. 11321 (2005 May) [online]. Available from URL: http://www.nber.org/papersAvll321 [Accessed 2007 Sep 12]

Garattini L, Ghislandi S. Should we really worry about “launch delays” of new drugs in OECD countries? Eur J Health Econ 2007; 8: 1–3PubMedCrossRef

Cohen J. Comment on: should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi. Eur J Health Econ 2007; 8 (2): 169–170PubMedCrossRef

Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996

Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54: 87–123PubMedCrossRef

Brekke KR, Konigbauer I, Straume OR. Reference pricing of pharmaceuticals. J Health Econ 2007; 26: 613–642PubMedCrossRef

Danzon PM, Ketcham JD. Medicare: evidence from Germany, the Netherlands, and New Zealand. Front Health Policy Res 2004; 7: 1–54PubMed

10.

Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21 (2): 89–103PubMedCrossRef

11.

Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 2005; 23 (7): 651–658PubMedCrossRef

12.

Stargardt T, Schreyogg J. Impact of cross-reference pricing on pharmaceutical prices: manufacturer’s pricing strategies and price regulation. Appl Health Econ Health Policy 2006; 5 (4): 235–247PubMedCrossRef

13.

Gress S, Niebuhr D, May U, et al. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios. Pharmacoeconomics 2007; 25 (6): 443–454PubMedCrossRef

14.

Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 2007; 82: 330–339PubMedCrossRef

15.

Haga A, Sverre JM. Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econ 2002; 3 (3): 215–220PubMedCrossRef

16.

Lee YC, Yang MC, Huang YT, et al. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996–2003. Pharmacoeconomics 2006; 24 (9): 891–902PubMedCrossRef

17.

Yfantopoulos J. Pharmaceutical pricing and reimbursement reforms in Greece. Eur J Health Econ 2008; 9 (1): 87–97PubMedCrossRef

18.

Antonanzas F, Oliva J, Pinillos M, et al. Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur J Health Econ 2007; 8: 297–300PubMedCrossRef

19.

Barry M, Tilson L, Ryan M. Pricing and reimbursement of drags in Ireland. Eur J Health Econ 2004; 5 (2): 190–194PubMedCrossRef

20.

Gregson N, Sparrowhawk K, Mauskopf J, et al. Pricing medicines: theory and practice, challenges and opportunities. Nature 2005; 4: 121–130

21.

Darba J, Rovira J. Parallel imports of pharmaceuticals in the European Union. Pharmacoeconomics 1998; 14 Suppl. 1: 129–136PubMedCrossRef

22.

Kanavos P. The single market for pharmaceuticals in the European Union in light of the European court of justice rulings. Pharmacoeconomics 2000; 18 (6): 523–532PubMedCrossRef

23.

Chaudhry PE, Walsh MG. Gray marketing of pharmaceuticals. J Health Care Mark 1995; 15 (3): 18–22PubMed

24.

West P, Mahon J. Benefits to payers and patients from parallel trade. York: York Health Economics Consortium, University of York May 2003

25.

Kanavos P, Costa-i-Font J, Merkur S, et al. The economic impact of pharmaceutical parallel trade in European Union member states: a stakeholder analysis [special research paper LSE Health and Social Care]. London: London School of Economics and Political Science, 2004

26.

Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J 2002; 43 (3): 453–461PubMed

27.

Kolassa EM. Elements of pharmaceutical pricing. New York: The Pharmaceutical Products Press, 1997

28.

Emilien G. Future European health care: cost containment, health care reform and scientific progress in drag research. Int J Health Plann Manage 1997; 12 (2): 81–101PubMedCrossRef

29.

Jelovac I, Bordoy C. Pricing and welfare implications of parallel imports in the pharmaceutical industry. Int J Health Care Finance Econ 2005; 5: 5–21PubMedCrossRef

30.

Nemhauser GL, Wolsey LA. Integer and combinatorial optimization. New York: Wiley-Interscience, 1988

31.

Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998; 44: 73–85PubMedCrossRef

32.

Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Rand J Econ 2002; 33 (3): 469–487CrossRef

33.

Decision Resources. The impact of German reference pricing of statins: implications for the pharmaceutical industry, 2005 Dec 1 [online]. Available from URL: http://www.market research.com/product/display.asp?.productid=1255340&g=l [Accessed 2007 Dec 4]

34.

Woodfield A. Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements. Pharmacoeconomics 2001; 19 (4): 365–377PubMedCrossRef

35.

Schneeweiss S, Soumerai SB, Glynn RJ, et al. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drag utilization. CMAJ 2002; 166 (6): 737–745PubMed

36.

Schneeweiss S, Dormuth C, Grootendorst P, et al. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004; 42 (7): 653–660PubMedCrossRef

37.

Grootendorst PV, Marshall JK, Holbrook AM, et al. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drags. Health Serv Res 2005; 40: 1297–1317PubMedCrossRef

38.

Angus DE, Karpetz HM. Pharmaceutical policies in Canada: issues and challenges. Pharmacoeconomics 1998; 14 Suppl. 1: 81–96PubMedCrossRef

39.

Grootendorst PV, Dolovich LR, O’Brien BJ, et al. Impact of reference-based pricing of nitrates on the use and costs of antianginal drugs. CMAJ 2001; 165 (8): 1011–1019PubMed

40.

Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilization, and health outcomes. Pharmacoeconomics 2002; 20 (9): 577–591PubMedCrossRef

41.

Kalo Z, Muszbek N, Bodrogi J, et al. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 2007; 80 (3): 402–412PubMedCrossRef

42.

Glynn D. Reimbursement for new health technologies: breakthrough pharmaceuticals as a 20th century challenge. Pharmacoeconomics 2000; 18 Suppl. 1: 59–67PubMedCrossRef

43.

Grossmann IE, Kravanja Z. Mixed-integer nonlinear programming: a survey of algorithms and applications. In: Biegler LT, Coleman TF, Conn AR, et al., editors. Large-scale optimization with applications: part II. Optimal design and control. Vol. 93. The IMA volumes in mathematics and its applications. Berlin, New York: Springer Verlag, 1997

Title: Assessing the Impact of Global Price Interdependencies
Author: Associate Professor Anke Richter
Publication date: 01-08-2008
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 8/2008
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200826080-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessing the Impact of Global Price Interdependencies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2008

Conducting Discrete Choice Experiments to Inform Healthcare Decision Making

Demand Forecasting for Preventive AIDS Vaccines

Trastuzumab

Modelling Approaches

Waiting for Reimbursement of New Medicines in Canada